

Interaction of *Bacillus subtilis* CsaA with SecA and precursor proteins

Jörg P. MÜLLER*¹, Jörg OZEGOWSKI†, Stefan VETTERMANN‡, Jelto SWAVING§, Karel H. M. VAN WELY§ and Arnold J. M. DRIESSEN§

*Institute for Molecular Biology, Jena University, Winzerlaer Strasse 10, D-07745 Jena, Germany, †Institute of Experimental Microbiology, Jena University, Winzerlaer Str. 10, D-07745 Jena, Germany, ‡ProThera GmbH, Winzerlaer Str. 10, D-07745 Jena, Germany, and §Department of Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Kerklaan 30, NL-9751 Haren, The Netherlands

CsaA from the Gram-positive bacterium *Bacillus subtilis* has been identified previously as a suppressor of the growth and protein-export defect of *Escherichia coli* *secA*(Ts) mutants. CsaA has chaperone-like activities *in vivo* and *in vitro*. To examine the role of CsaA in protein export in *B. subtilis*, expression of the *csaA* gene was repressed. While export of most proteins remained unaffected, export of at least two proteins was significantly reduced upon CsaA depletion. CsaA co-immunoprecipitates and co-purifies with the SecA proteins of *E. coli* and *B. subtilis*, and binds the *B. subtilis* preprotein prePhoB. Purified CsaA

stimulates the translocation of prePhoB into *E. coli* membrane vesicles bearing the *B. subtilis* translocase, whereas it interferes with the SecB-mediated translocation of proOmpA into membrane vesicles of *E. coli*. The specific interaction with the SecA translocation ATPase and preproteins suggests that CsaA acts as a chaperone that promotes the export of a subset of preproteins in *B. subtilis*.

Key words: chaperone, co-immunoprecipitation, co-purification, *in vitro* translocation, protein translocation.

INTRODUCTION

In Eubacteria, proteins can be translocated across the cytoplasmic membrane and secreted into the medium. These proteins are usually synthesized as precursors with an N-terminal extension, the signal peptide (for review, see [1]), which is essential for directing them into the export pathway (for review, see [2]). Genetically and biochemically the best-characterized bacterial export system is that of *Escherichia coli* (for reviews, see [2,3]). This system, termed preprotein translocase, consists of the peripheral membrane protein SecA [4] and a multi-subunit membrane-protein complex with SecY, SecE and SecG as subunits [5]. The SecYEG complex acts as a receptor for SecA, and functions as a preprotein-conducting channel [6,7]. During or shortly after the translocation of the preprotein across the membrane, the signal peptide is removed by signal peptidase(s) (for review, see [8]), a prerequisite for the release of the mature protein from the membrane [9]. The integral membrane proteins SecD and SecF [10] are not essential for precursor protein translocation but, when overproduced, stabilize the SecYEG-bound SecA in a membrane-inserted state [11].

Whereas bacterial protein translocation is largely uncoupled from ongoing translation [12], efficient export requires chaperones to maintain preproteins in a translocation-competent state and to target them to the membrane-associated part of the translocase. In *E. coli*, SecB is an export-dedicated cytosolic chaperone that is required for efficient export of a subset of preproteins [13]. SecB stabilizes preproteins in an unfolded, non-aggregated state [14], and binds post-translationally or at the late co-translational stage to the mature region of these proteins [15]. The SecB–preprotein complex is then targeted to the SecYEG-bound SecA. The preprotein is subsequently transferred from SecB to SecA, and, upon the ATP-dependent initiation of translocation, the SecB is released into the cytosol [3]. *In vivo*, only a subset of preproteins appears to be translocated in a SecB-

dependent manner [2]. A second targeting factor, consisting of the Ffh protein and the 4.5 S RNA, assists the export of SecB-independent exported proteins [16]. Other molecular chaperones, such as the heat-shock proteins DnaK/DnaJ/GrpE [17–19] and GroEL/GroES [20], appear also to be involved under specific conditions.

The central components of the protein-translocation system of *B. subtilis* are similar to those of *E. coli*. So far, homologues of Ffh, 4.5 S RNA, SecA, SecY, SecE, SecG, SecDF and several type-I signal peptidases have been identified (for review see [21]).

So far, it is unknown if chaperones are involved in protein translocation in *B. subtilis*. *B. subtilis* lacks a SecB homologue [22] and this has raised the question of whether other chaperones are involved in protein translocation. Depletion of signal-recognition-peptide (SRP) components impairs protein translocation [23,24], and the *B. subtilis* Ffh interacts directly with SecA and promotes the formation of soluble SecA–preprotein complexes [25]. This has led to the suggestion that SRP of *B. subtilis* not only acts as a targeting factor in co-translational translocation, but also stimulates post-translational translocation of preproteins [25]. The *B. subtilis* CsaA protein specifies chaperone-like activities possibly related to protein translocation [26]. The *csaA* gene was identified as a suppressor of growth and secretion defects of *E. coli* *secA*(Ts) strains [27]. Presence of CsaA stimulated precursor processing in *secA*, *secB*, *groEL* and *dnaJ* mutant strains of *E. coli* and it suppressed the growth defects of *dnaK*, *dnaJ* and *grpE* mutants of *E. coli*. CsaA stimulates the reactivation of heat-denatured firefly luciferase in *groEL*, *groES*, *dnaK* and *grpE* mutant strains of *E. coli*, and prevents the aggregation of heat-denatured luciferase *in vitro*. The exact mechanism by which CsaA suppresses the growth and secretion defects of *E. coli* *secA*(Ts) strains is unknown. CsaA may either improve the translocation-competence of exported preproteins, thereby making them better substrates for mutant SecA proteins, or stimulate the translocation activity of the

Abbreviations used: NaP_i, inorganic phosphate, NaH₂PO₄; His₆-CsaA, hexa-histidine-tagged CsaA; His₆-SecB, hexa-histidine-tagged SecB; His₆-prePhoB, hexa-histidine-tagged prePhoB; IPTG, isopropyl β-D-thiogalactoside; Ni-NTA, Ni²⁺-nitrilotriacetate; SRP, signal recognition peptide.

¹ To whom correspondence should be addressed (e-mail jmueller@imb-jena.de).

mutant SecA proteins. Expression of CsaA in *E. coli* suppresses synthesis of SecB [26], whereas an impaired function of general chaperones causes an elevation in SecB expression [28]. These data further suggest a chaperone function of CsaA that could possibly be related to protein translocation.

In this paper we have further examined the role of CsaA in protein translocation in *B. subtilis*. CsaA affects the efficient secretion of some preproteins, and interacts specifically with SecA and preproteins. The data suggest that CsaA acts as a chaperone that promotes the export of a subset of preproteins in *B. subtilis*.

EXPERIMENTAL

Bacterial strains, plasmids and media

Bacterial strains and plasmids used in this study are listed in Table 1. Strains were grown in TY medium (Bacto Tryptone/Bacto Yeast extract) or on TY plates [28]. Pulse labelling of *B. subtilis* was carried out in defined HPDM medium [29], casamino acids were replaced by amino acids (0.02 mg/ml) excluding methionine and cysteine. If required, ampicillin (80 µg/ml), erythromycin (5 µg/ml) or kanamycin (20 µg/ml) were added.

Biochemicals

B. subtilis SecA [32], *E. coli* SecA [33] and the *B. subtilis* GroELS complex [34] were isolated from overproducing strains as described. proOmpA [7] and hexa-histidine-tagged prePhoB (His₆-prePhoB) [35] were purified as described. Purified proOmpA, prePhoB and SecA proteins were labelled with carrier-free ¹²⁵I according to van Wely et al. [35]. Labelled preproteins were stored frozen in 6 M urea. Polyclonal antiserum was raised

against purified hexa-histidine-tagged CsaA (His₆-CsaA). Antisera against SecA from *B. subtilis* were from R. Freudl (Forschungszentrum Jülich, Jülich, Germany). Membrane vesicles were prepared from *E. coli* strain SF100 [36] containing plasmid pET605 overproducing SecYEG from *E. coli* [37] or plasmid pET822 overproducing SecYEG from *B. subtilis* DB104 as described in [38]. Membrane vesicles were treated with polyclonal antibodies against *E. coli* SecA to deplete and inactivate the endogenous SecA [38].

DNA manipulation/techniques

Procedures for DNA purification, restriction, ligation, transformation of *E. coli* and agarose-gel electrophoresis were carried out as described by Sambrook et al. [39]. The nucleotide sequences of cloned PCR fragments were confirmed by DNA sequencing.

To amplify *csaA'*, oligonucleotides 5'-TCTCGAATTCAAT-AGGAGAAAAAGGAGTT⁵⁷⁴-3', localized 5' to the ribosome-binding site of *csaA* and incorporating an *EcoRI* restriction site, and 5'-GGACCAAGGGATCCGATTTAAAT-CCGGCG⁸⁰⁵-3', localized within *csaA* and incorporating a *BamHI* restriction site, were used (the numbers refer to those in Müller et al. [27]). The *csaA'* gene was amplified by PCR from *B. subtilis* chromosomal DNA. The amplified fragment was digested with *EcoRI* and *BamHI* and cloned into pMUTIN2 [40] digested with the same enzymes. The resulting plasmid pMUTIN *csaA'* was integrated into the chromosome of *B. subtilis* DB104 via Campbell-type integration.

For synthesis of His-tagged proteins *secB* and *csaA* genes were amplified excluding their ATG start codons and were inserted 3' to the His-coding region of pQE9. Genes were amplified by PCR using oligonucleotides 5'-CACGGATCCGAACAAACAAC-ACTG¹⁰³-3', incorporating a *BamHI* restriction site, and 5'-CCGACTGCAGTCATTGAAGCATTACG⁵⁵⁸-3', with a *PstI* restriction site, for *secB* (the numbers refer to those used in [41]), and oligonucleotides 5'-GGAGTTATTGGATCCGCAGTTA-TTGATGAC⁵⁹⁸-3', with a *BamHI* restriction site, and 5'-GCC-GATCTCTGCAGGCCTTTACGGCACACACG⁹⁸¹-3', incorporating a *PstI* restriction site, for *csaA* (the numbers refer to those used in [27]). PCR fragments were purified, digested with *BamHI* and *PstI* and inserted into pQE9 digested with the same enzymes. The resulting plasmids pQE9secB and pQE9csaA were transformed into *E. coli* TG1(pREP4).

Pulse-chase protein labelling and analysis of protein secretion

Pulse-chase protein-labelling experiments were performed as described by van Dijl et al. [42]. *B. subtilis* was grown in minimal medium to exponential growth in the absence or presence of 1 mM isopropyl β-D-thiogalactoside (IPTG), pulse labelled with [³⁵S]methionine for 1 min and subsequently chased. Samples were taken 2 and 5 min post chase time and proteins secreted into the growth medium were collected as described in [43]. SDS/PAGE was performed according to Laemmli [44]. ¹⁴C-Methylated proteins (Amersham International, Amersham, Bucks, U.K.) were used as molecular-size markers. Relative amounts of radioactivity were estimated by using a PhosphoImager (Fuji) and associated image-analysis software.

Purification of proteins

His₆-CsaA and hexa-histidine-tagged SecB (His₆-SecB) were prepared from IPTG-induced *E. coli* TG1(pREP4, pQE9csaA) and TG1(pREP4, pQE9secB) cultures as abundant proteins and purified by Ni²⁺-nitrilotriacetate (Ni-NTA) agarose affinity chromatography. Purification was carried out under native

Table 1 Bacterial strains and plasmids, and their genotype/phenotypes

IPTG, isopropyl β-D-thiogalactoside; His₆-CsaA, hexa-histidine-tagged CsaA; His₆-SecB, hexa-histidine-tagged SecB.

Strain/plasmid	Relevant genotype/phenotype	Reference
Strains		
<i>B. subtilis</i>		
DB104	<i>his, nprE, aprE</i>	[30]
DB104::pMUTIN <i>csaA'</i>	DB104, allows IPTG-inducible expression of <i>csaA</i>	This study
<i>E. coli</i>		
TG1	<i>hsdD5/F traD36, proA⁺B⁺, Δ(lac-pro) lacIQ, lacZ ΔM15</i>	[31]
TG1(pREP4)	Host for overexpression of His-tagged proteins	This study
TG1(pREP4, pQE9 <i>csaA</i>)	TG1 derivative strain, Km ^r , Ap ^r , allows IPTG-inducible synthesis of His ₆ -CsaA	This study
TG1(pREP4, pQE9 <i>secB</i>)	TG1 derivative strain, Km ^r , Ap ^r , allows IPTG-inducible synthesis of His ₆ -SecB	This study
Plasmids		
pMUTIN2	pBR322-based integration vector for <i>B. subtilis</i> ; containing IPTG-inducible P _{spac} promoter, Ap ^r , Em ^r	[40]
pMUTIN <i>csaA'</i>	pMUTIN2 derivative; carries the 5' part of <i>csaA</i>	
pREP4	plasmid, containing <i>lacI^q</i> repressor gene, Km ^r	Qiagen
pQE9	pBR322-based vector for IPTG-inducible synthesis of His ₆ -tagged proteins, Ap ^r	Qiagen
pQE9 <i>csaA</i>	pQE9 derivative plasmid, Ap ^r , allows IPTG-inducible synthesis of His ₆ -CsaA	This study
pQE9 <i>secB</i>	TG1 derivative plasmid, Ap ^r , allows IPTG-inducible synthesis of His ₆ -SecB	This study

conditions following standard protocols (Qiagen, Hilden, Germany). Cell lysates prepared in 50 mM NaP_i (inorganic phosphate, NaH₂PO₄), pH 8.0, and 300 mM NaCl, were supplemented with 10 mM imidazole and applied on to the Ni-NTA column. The column was washed three times with several column volumes of NaP_i buffer containing 20 mM imidazole. His-tagged proteins were eluted with NaP_i buffer containing 500 mM imidazole.

CsaA from *B. subtilis* was purified immunologically. Affinity-purified rabbit antibodies against CsaA were covalently linked to CNBr-activated Sepharose. Exponentially grown *B. subtilis* DB104 cells were harvested and extracts were prepared from lysozyme-treated cells via sonication. Cleared cell extracts were loaded on to the anti-CsaA-Sepharose column at room temperature. Anti-CsaA-Sepharose was washed with 30 ml of phosphate buffer (50 mM, pH 7.0) containing 0.5 M NaCl until no detectable protein was eluted from the column. CsaA was eluted with 0.1 M acetic acid, pH 3.0, and subsequently lyophilized. To obtain SecA-free CsaA *B. subtilis* cell extracts were purified by preparative isoelectric focusing in Sephadex gel with a pH gradient from pH 4.0 to 9.0 for 18 h. After focusing, the Sephadex gel was cleaved to fractions and CsaA-containing fractions (as determined immunologically) were analysed by thin-layer polyacrylamide gel isoelectric focusing with an ampholyte solution (pH 3.5–10.0) and SDS/PAGE. The CsaA was precipitated with ammonium sulphate to a final concentration of 80% saturation. The precipitated protein was dissolved, dialysed against H₂O and lyophilized.

Western blotting

Proteins isolated from exponentially growing cultures were assayed by Western blotting [45]. Cell lysates were prepared by boiling (5 min) in sample buffer and subjected to SDS/PAGE [44]. Separated proteins were transferred to a nitrocellulose membrane (Schleicher & Schüll), as described by Towbin et al. [45]. CsaA and SecA proteins were detected with specific polyclonal antibodies and alkaline phosphatase-conjugated goat anti-rabbit antibodies (Bio-Rad) according to the manufacturer's instructions. Similar amounts of total cell protein were loaded on to each lane.

Binding studies

Binding of [¹²⁵I]His₆-prePhoB or [¹²⁵I]SecA to CsaA was measured as follows: 1 µg of ¹²⁵I-labelled protein and 1 µg of CsaA were incubated at room temperature in 50 µl of Hepes buffer (50 mM, pH 7.6, additional buffer components as indicated). After 60 min, 5 µl of CsaA-specific antiserum pre-complexed with 5 mg of Protein A-Sepharose was added and the mixture was further incubated for 60 min with regular vortexing. Subsequently, the Protein A-Sepharose beads were washed five times with 500 µl of Hepes buffer, pH 7.6. ¹²⁵I-labelled proteins bound to Protein A-Sepharose beads were counted in Optima Gold scintillation liquid (Packard Instruments B.V., Groningen, The Netherlands).

Translocation assay

The efficiency of translocation *in vitro* of [¹²⁵I]proOmpA and [¹²⁵I]prePhoB into *E. coli* membrane vesicles was assayed by treatment with proteinase K [46]. When indicated, 1.0 µg of purified *E. coli* or *B. subtilis* SecA protein, 2.0 µg of *E. coli* SecB or 4 µg of purified *B. subtilis* GroESL or *B. subtilis* CsaA were added. Reactions were started by the addition of 1 µl of ¹²⁵I-labelled precursor protein (0.5 µg of protein). For preincubation

experiments, mixtures were incubated for 30 min at 37 °C without membrane vesicles prior to the translocation reactions. After 30 min of translocation at 37 °C samples were chilled on ice, treated with proteinase K (0.5 mg/ml) for 15 min, precipitated with 7.5% trichloroacetic acid, washed with acetone, dissolved in SDS/PAGE sample buffer, and analysed by SDS/PAGE (10% gel) and autoradiography.

RESULTS

Repression of CsaA expression results in alteration of protein secretion

In *B. subtilis* strain DB104::pMUTIN2*csaA'*, *csaA* is localized downstream of the P_{spac} promoter, allowing the IPTG-inducible expression of the CsaA protein. Cells grown in the absence of IPTG were normally viable but Western-blotting analysis showed that they contained a dramatically reduced cellular level of CsaA. Induction of the P_{spac} promoter resulted in a production level of CsaA that was about 2-fold higher than in the wild type (Figure 1A). To study the function of CsaA in protein secretion, the pattern of proteins secreted by *B. subtilis* DB104::pMUTIN2*csaA'* grown in the absence or presence of IPTG was determined. While the pattern of secreted proteins of the strain grown in presence of IPTG was indistinguishable from that of the wild type, repression of *csaA* expression resulted in a decrease in at least two proteins with apparent molecular masses of 19 and 36 kDa (Figure 1B). In particular, the 36-kDa protein




Figure 1 Repression of *csaA* in *B. subtilis* affects protein export

(A) *B. subtilis* strain DB104 (lane 1) and strain DB104::pMUTIN2*csaA'* (lanes 2 and 3) were grown in TY medium in the absence (lanes 1 and 2) or presence (lane 3) of 1 mM IPTG. Cell extracts were analysed by SDS/PAGE and Western blotting using CsaA-specific antibodies. (B) Protein secretion of *B. subtilis* DB104::pMUTIN2*csaA'* was analysed by pulse labelling of cells grown in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of IPTG. Secreted proteins were collected by filtration and analysed by SDS/PAGE and autoradiography.




Figure 2 *E. coli* SecA interacts with His₆-CsaA and His₆-SecB

E. coli strains TG1(pREP4, pQE9csaA) (A, B), TG1(pREP4, pQE9secB) (C) and TG1(pREP4, pQE9) (D) were cultivated in TY medium to exponential growth and the phage T5 promoter was derepressed by adding IPTG (final concentration, 2 mM) to the culture medium. After 2 h, cells were harvested and lysed by sonication, and the cleared cell extracts were loaded on to Ni-NTA columns. Aliquots of non-bound fraction (FT, lane 1), wash (W1–W3, lanes 2–4) and elution fractions (E1–E8, lanes 5–12) were analysed by SDS/PAGE and Western blotting using antibodies directed against CsaA (A) and *E. coli* SecA (B–D). The asterisk indicates the position of dimeric CsaA.

seemed completely absent in the supernatant of CsaA-depleted cells. Both protein bands were isolated from Coomassie Brilliant Blue-stained SDS/PAGE, and N-terminally sequenced. While the N-terminus of the 36-kDa protein appeared blocked, the N-terminus of the 19-kDa protein corresponded to KENHTFSGED. This amino acid sequence matched the amino acid residues 33–42 of the precursor of YvaY, a protein with unknown function and a calculated molecular mass of 18.8 kDa.

E. coli SecA co-purifies with His₆-CsaA and His₆-SecB

His-tagged CsaA protein was overproduced in *E. coli* TG1 (pREP4, pQE9csaA) and purified by Ni-NTA-column chromatography. The imidazole-eluted protein fraction predominantly contained the 13-kDa CsaA protein, and a protein with an apparent molecular mass of about 30 kDa that stained with antibodies directed against CsaA (Figure 2A). The latter probably represents some dimeric CsaA. Immunodetection with




Figure 3 *B. subtilis* SecA co-purifies with CsaA

A cell lysate of *B. subtilis* DB104 was loaded on to an anti-CsaA–Sepharose column, washed with NaCl buffer (0.5 M) and the immunologically bound CsaA was eluted with 0.1 M acetic acid. The eluate was analysed by SDS/PAGE and Coomassie Brilliant Blue staining (lane 1) or Western blotting using polyclonal antibodies (pAb) directed against the *B. subtilis* SecA (lane 2) or CsaA (lane 4). The asterisk indicates the localization of dimeric CsaA. As a control, a lysate of *B. subtilis* DB104::pMUTIN2csaA' grown in the absence of IPTG was loaded on to the anti-CsaA–Sepharose column, and the fraction eluted with 0.1 M acetic acid was stained immunologically with antibodies directed against the *B. subtilis* SecA (lane 3).

SecA antibodies revealed that SecA co-eluted with CsaA from the column (Figure 2B). To exclude the possibility that SecA non-specifically binds to the Ni-NTA resin, a lysate of *E. coli* TG1(pREP4) cells that do not express the His-tagged CsaA was loaded on to an Ni-NTA column (Figure 2D). Under those conditions, no SecA was retained by the column, suggesting an interaction between CsaA and SecA. Since SecA is known to interact with SecB in *E. coli* [6,7,47], His₆-SecB was purified from *E. coli* TG1(pREP4,pQE9secB) under conditions used for purification of His₆-CsaA. SecA was found to co-elute with His₆-SecB (Figure 2C). These results indicate that SecA was retained in the Ni-NTA column via specific binding to His-tagged CsaA or SecB.

B. subtilis SecA interacts with CsaA

To establish whether the interaction of CsaA with SecA can be observed in *B. subtilis*, CsaA was purified from *B. subtilis* DB104. Cell extracts were loaded on to an anti-CsaA–Sepharose column, washed and eluted as described in the Experimental section. The eluate was analysed by SDS/PAGE and Coomassie Brilliant Blue staining (Figure 3, lane 1). In addition to CsaA, a protein co-eluted with an apparent molecular mass of about 90 kDa. The latter could be immunostained with an antibody directed against the *B. subtilis* SecA (Figure 3, lane 2), suggesting that the *B. subtilis* SecA associates with CsaA. As a control, a lysate of *B. subtilis* DB104::pMUTIN2csaA' grown in the absence of IPTG was used. Under those conditions, CsaA was not expressed (Figure 1A, lane 2) and no SecA was found to bind to the anti-CsaA–Sepharose column (Figure 3, lane 3).

Since the data *in vivo* suggest a specific interaction between SecA and CsaA, the interaction was examined further using

Table 2 Co-immunoprecipitation of CsaA with *E. coli* and *B. subtilis* SecA

Purified CsaA and [¹²⁵I]SecA proteins from *E. coli* or *B. subtilis* were mixed in 50 mM Hepes, pH 7.6, supplemented with 60 mM urea and 1.25% octylglucoside. After 60 min of incubation at room temperature, CsaA- or *E. coli* or *B. subtilis* SecA-specific antibodies pre-complexed with Protein A–Sepharose were added and the incubation was continued for another 60 min. Immunoprecipitates were collected by centrifugation and the amount of bound SecA was quantified by liquid scintillation counting. Amounts of radiolabelled SecA (means ± S.D. from two independent experiments) are shown in c.p.m. pAb, polyclonal antibody.

CsaA	CsaA pAb	SecA pAb	Bound [¹²⁵ I]SecA (c.p.m.)	
			<i>E. coli</i>	<i>B. subtilis</i>
+	+	–	3140 ± 10	470 ± 106
+	–	–	948 ± 470	100 ± 6
–	+	–	1198 ± 75	176 ± 32
–	–	–	889 ± 3	139 ± 5
–	–	+	9724 ± 100	2170 ± 15

Table 3 Co-immunoprecipitation of CsaA with *B. subtilis* prePhoB

Purified CsaA and [¹²⁵I]His₆-prePhoB were mixed in 50 mM Hepes, pH 7.6, supplemented with 60 mM urea and 1.25% octylglucoside. After a 60-min incubation at room temperature, CsaA- or prePhoB-specific antibodies pre-complexed with Protein A–Sepharose were added and the incubation was continued for another 60 min. Immunoprecipitates were collected by centrifugation and the amount of bound prePhoB was quantified by liquid scintillation counting. pAb, polyclonal antibody.


CsaA	CsaA pAb	PhoB pAb	Bound [¹²⁵ I]PhoB (c.p.m.)
+	+	–	1199
+	–	–	75
–	+	–	292
–	–	–	329
–	–	+	4291

purified proteins. CsaA was co-incubated with ¹²⁵I-labelled *E. coli* and *B. subtilis* SecA. Complex formation was analysed by immunoprecipitation of CsaA. To differentiate between CsaA-mediated and non-specific binding of SecA to Protein A–Sepharose, CsaA and/or antiserum against CsaA were excluded from the reaction mixture. In the presence of CsaA, both the *E. coli* and *B. subtilis* SecA proteins could be immunoprecipitated by the CsaA antibodies (Table 2). Background levels of immunoprecipitation were observed when either CsaA (Table 2) or the CsaA antibodies were excluded from the reaction mixture. These results suggest that SecA and CsaA are interacting proteins.

CsaA binds the preprotein prePhoB and stimulates its translocation *in vitro*

CsaA interacts with unfolded proteins [26]. To determine if CsaA also interacts with unfolded preproteins, urea-denatured *B. subtilis* preprotein [¹²⁵I]His₆-prePhoB at 1 mg/ml was diluted 100-fold into a buffer containing 10 µg/ml CsaA protein. Complex formation was assessed by immunoprecipitation with a CsaA antibody. A substantial amount of the His₆-prePhoB could be co-immunoprecipitated with CsaA (Table 3), whereas only low levels of prePhoB were immunoprecipitated when either the CsaA (Table 3) or the CsaA antibodies were excluded from the reaction mixture.

His₆-prePhoB was used previously to demonstrate preprotein translocation into *E. coli* membrane vesicles derived from a

**Figure 4** Effect of CsaA on the SecA-mediated translocation of prePhoB into membrane vesicles of *E. coli* containing *B. subtilis* SecYEG

Translocation of [¹²⁵I]His₆-prePhoB in membrane vesicles was carried out in the absence (lane 1) and presence (lanes 2–6) of exogenous SecA, and the presence of GroELS complex (1 µg, lane 3) or CsaA (0.5 µg, lane 4; 2 µg, lane 5; 5 µg, lane 6). After translocation, samples were treated with proteinase K and analysed by SDS/PAGE and autoradiography. p, precursor; m, mature protein.

strain that overexpresses the SecYEG complex of *B. subtilis* [38]. The ATP-dependent translocation of urea-denatured [¹²⁵I]His₆-prePhoB by *E. coli* membrane vesicles bearing SecYEG and SecA from *B. subtilis* was examined using the proteinase digestion assay. While in the absence of SecA (Figure 4, lane 1) or ATP (results not shown) hardly any translocation of [¹²⁵I]His₆-prePhoB occurred, efficient translocation was observed when the membrane vesicles were supplemented with purified *B. subtilis* SecA (Figure 4, lane 2). Addition of *B. subtilis* GroESL complex or increasing amounts of CsaA (Figure 4, lanes 4–6) further stimulated the translocation of [¹²⁵I]His₆-prePhoB. To establish if the stimulatory effect of CsaA is related to maintenance of the translocation competence of [¹²⁵I]His₆-prePhoB, experiments were performed in which [¹²⁵I]His₆-prePhoB was diluted 50-fold into buffer in the absence and presence of CsaA, followed by a 30-min preincubation at 37 °C. However, under these conditions prePhoB hardly exhibited a loss in translocation competence (results not shown), suggesting that CsaA may stimulate translocation by another mechanism.

CsaA interferes with SecB for translocation of proOmpA into *E. coli* membrane vesicles

Since CsaA interacts with preproteins and with SecA, an activity reminiscent of SecB, we determined if CsaA is able to substitute for SecB in the translocation of [¹²⁵I]proOmpA into *E. coli* membrane vesicles that contain elevated levels of *E. coli* SecYEG complex. Urea-denatured [¹²⁵I]proOmpA was preincubated in buffer for 30 min in the absence or presence of SecB or CsaA. In the absence of SecB, the translocation activity of the preincubated [¹²⁵I]proOmpA was largely abolished (Figure 5A, compare lanes 2 and 3). Preincubation of proOmpA with CsaA did not maintain the translocation competence of proOmpA (Figure 5A, lanes 4–6). Next, the effect of co-incubation of CsaA and SecB with proOmpA was determined (Figure 5B). The amount of translocated [¹²⁵I]proOmpA decreased with the concentration of CsaA present in the pre-incubation mixture (Figure 5B). When CsaA was added at the end of the SecB–proOmpA pre-incubation period, the inhibitory effect of CsaA on the translocation of [¹²⁵I]proOmpA was still evident (Figure 5C). The data indicate that CsaA interferes with the ability of SecB to promote proOmpA translocation.




Figure 5 Translocation of proOmpA by *E. coli* membrane vesicles containing overproduced *E. coli* SecYEG

Translocation of [¹²⁵I]proOmpA into membrane vesicles was performed as described in the Experimental section. **(A)** proOmpA was pre-incubated for 30 min at 37 °C in the absence (lane 1), or presence of SecA (1 µg; lane 2) and SecB (1 µg; lane 3) or CsaA (0.1 µg, lane 4; 0.5 µg, lane 5; 1 µg, lane 6; 5 µg, lane 7). **(B)** proOmpA was pre-incubated for 30 min at 37 °C in the presence of SecA and SecB (1 µg each) and CsaA (0.1 µg, lane 1; 0.5 µg, lane 2; 1 µg, lane 3; 5 µg, lane 4). **(C)** as **(B)** except that CsaA was added at the end of the pre-incubation period. Translocation was assayed after the pre-incubation period by the addition of membrane vesicles, and was performed as described in the Experimental section. p, precursor; m, mature protein.

DISCUSSION

The cytosolic *B. subtilis* protein CsaA has been identified as a suppressor of *E. coli* secA mutations [26]. CsaA has chaperone-like activities both *in vivo* and *in vitro* [26]. We have now studied the role of CsaA in protein translocation in *B. subtilis* using an *in vitro* translocation system [35,38]. The data indicate that CsaA is able to interact with the *B. subtilis* preprotein prePhoB and the translocation ATPase SecA, and that this interaction results in a stimulation of prePhoB translocation. Moreover, repression of the *csaA* gene in *B. subtilis* results in a reduction of the secretion efficiency of at least two proteins. Such interactions are reminiscent of the secretion-dedicated function of the molecular chaperone SecB in *E. coli* [15]. Since *B. subtilis* lacks a protein homologous to SecB [22], CsaA may fulfil a similar function for a specific subset of preproteins to the *E. coli* SecB.

As a heterologous component, CsaA suppresses export and chaperone defects in *E. coli* [26,27]. To study the function of

CsaA in protein export in *B. subtilis*, protein export was analysed in response to *csaA* suppression. Earlier extensive gene-disruption experiments failed [27], suggesting that *csaA* is an essential gene of *B. subtilis*. Therefore, *csaA* was placed under transcriptional control of the P_{spac} promoter using the integrative plasmid pMUTIN2 [40]. Despite the fact that CsaA could not be detected in the absence of IPTG (Figure 1A), no alteration of growth was observed for *B. subtilis* DB104::pMUTIN2*csaA'* when grown in complex or defined medium. The possibility that minimal expression of CsaA, beyond the detection limit, suffices to sustain growth of this strain in the absence of IPTG cannot be excluded. Whereas in the presence of IPTG, protein secretion was essentially similar to the parental strain, repression of *csaA* resulted in a reduced export of at least two proteins at the end of the exponential growth phase.

An interaction between CsaA and *E. coli* or *B. subtilis* SecA could be demonstrated by various techniques. *E. coli* SecA copurifies with His₆-tagged CsaA on an Ni-NTA affinity resin, while the *B. subtilis* SecA was found to specifically co-purify with CsaA by means of an immuno-purification technique. Likewise, *E. coli* SecA co-purifies with His₆-SecB using the Ni-NTA-affinity column-chromatography technique. Since the latter interaction has been established previously [6], it suggests that the CsaA–SecA complex is also stable. No other proteins were co-purified in detectable amounts. The markedly lower retention of SecA in the presence of His₆-CsaA compared with the retention by His₆-SecB might have been due to the heterologous character of CsaA when expressed in *E. coli*. The interaction between CsaA and SecA could be demonstrated further *in vitro* by a co-immunoprecipitation of ¹²⁵I-labelled purified proteins. In *E. coli*, SecB binds to a well-conserved C-terminal region of SecA [7]. When fused to glutathione S-transferase, the 20 C-terminal amino acids of *E. coli* SecA represent an authentic SecB-binding domain. This glutathione S-transferase-fusion protein, however, does not interact with CsaA (J. P. Müller, J. Swaving, K. H. M. van Wely and A. J. M. Driessen, unpublished work), indicating that other domains of SecA are involved in this binding reaction. Interaction of CsaA with unfolded preproteins could be demonstrated by co-immunoprecipitation of His₆-prePhoB via CsaA. Similar experiments with radiolabelled proOmpA suggest that CsaA also interacts with this precursor (J. P. Müller, J. Swaving, K. H. M. van Wely and A. J. M. Driessen, unpublished work). Interaction of CsaA with these unfolded precursors is not unexpected since CsaA can also interact with other unfolded proteins [26].

The exact mechanism of suppression of impaired activity of the temperature-sensitive SecA proteins has not yet been established. CsaA may act by improving the translocation-competence of exported preproteins, thereby making them better substrates for the malfunctioning SecA proteins, or it may act directly on the activity of SecA [25]. Our current data suggest that it may stimulate translocation by improving the targeting to SecA as it binds SecA specifically.

In *E. coli*, chaperones are needed to support translocation of preproteins *in vitro*. SecB is required for a subset of preproteins [14,48], while other chaperones such as GroES/GroEL or DnaK/DnaJ/GrpE support translocation under certain conditions only [49]. In *B. subtilis*, no chaperones have thus far been found that stimulate preprotein translocation, although this function may be fulfilled by SRP, which has been shown to interact with SecA, thereby promoting the formation of soluble SecA–preprotein complexes [24]. Here we have shown that CsaA stimulates the translocation *in vitro* of prePhoB into membrane vesicles by about 2–3-fold. It is important to note that prePhoB only slowly loses its translocation competence when diluted from

urea, suggesting that the stimulation is due to targeting. More striking is the observation that CsaA competes with SecB for proOmpA translocation. When proOmpA is preincubated with a mixture of SecB and CsaA, SecB is no longer able to stimulate the translocation of proOmpA. In this context, it is important to note that CsaA itself does not stimulate the translocation of proOmpA, nor is it able to maintain the translocation competence of proOmpA. Since the inhibitory effect of CsaA is less pronounced when proOmpA is first pre-incubated with SecB, it seems that competition is mainly at the level of binding of the precursor, thus preventing SecB to target proOmpA to the translocation sites while maintaining its translocation competence. Elucidation of the mechanism of inhibition may provide further insight into the function of CsaA.

Taken together, the results *in vivo* and *in vitro* indicate that CsaA is able to bind to both *B. subtilis* preproteins and the SecA translocation ATPase, suggesting an export-related function of CsaA in *B. subtilis*. Depletion of CsaA in *B. subtilis* gives rise to an export defect of a set of proteins. Analysis of the translocation of these proteins in *B. subtilis* will further define the function of CsaA in protein secretion.

These investigations were supported by a short-term EMBO fellowship to J.P.M., by grants from the Deutsche Forschungsgemeinschaft, and by grants to A.J.M.D. from GEC Biotech nos. BIO2 CT 930254 and BIO4 CT 960097.

REFERENCES

- Von Heijne, G. (1990) *J. Membrane Biol.* **115**, 195–201
- Wickner, W., Driessen, A. J. M. and Hartl, F.-U. (1991) *Annu. Rev. Biochem.* **60**, 101–124
- Fekkes, P. and Driessen, A. J. M. (1999) *Microbiol. Mol. Biol. Rev.* **63**, 161–173
- Oliver, D. B. and Beckwith, J. (1982) *Cell* **330**, 311–319
- Douville, K., Price, A., Eichler, J., Economou, A. and Wickner, W. (1995) *J. Biol. Chem.* **270**, 20106–20111
- Hartl, F.-U., Lecker, S., Schiebel, E., Hendrick, J. P. and Wickner, W. (1990) *Cell* **63**, 269–279
- Fekkes, P., van der Does, C. and Driessen, A. J. M. (1997) *EMBO J.* **16**, 6105–6113
- Dalbey, R. E., Lively, M. O., Bron, S. and van Dijl, J. M. (1997) *Protein Sci.* **6**, 1129–1138
- Dalbey, R. E. and Wickner, W. (1985) *J. Biol. Chem.* **260**, 15925–15931
- Gardel, C., Johnson, K., Jacq, A. and Beckwith, J. (1990) *EMBO J.* **10**, 3209–3216
- Economou, A., Pogliano, J. A., Beckwith, J., Oliver, D. B. and Wickner, W. (1995) *Cell* **83**, 1171–1181
- Randall, L. L. and Hardy, S. J. S. (1995) *Trends Biochem. Sci.* **20**, 65–69
- Kumamoto, C. A. and Beckwith, J. (1985) *J. Bacteriol.* **163**, 267–274
- Lecker, S., Lill, R., Ziegelhofer, T., Georgopoulos, C., Bassford, P. J., Kumamoto, C. A. and Wickner, W. (1989) *EMBO J.* **8**, 2703–2709
- Kumamoto, C. A. and Francetic, O. (1993) *J. Bacteriol.* **175**, 2184–2188
- Phillips, G. J. and Silhavy, T. J. (1992) *Nature (London)* **359**, 744–746
- Wild, J., Altman, E., Yura, T. and Gross, C. A. (1992) *Genes Dev.* **6**, 1165–1172
- Wild, J., Rossmeyssl, P., Walter, W. A. and Gross, C. A. (1996) *J. Bacteriol.* **178**, 3608–3616
- Wild, J., Walter, W. A., Gross, C. A. and Altman, E. (1993) *J. Bacteriol.* **175**, 3992–3997
- Kusukawa, N., Yura, T., Ueguchi, C., Akiyama, Y. and Ito, K. (1989) *EMBO J.* **8**, 3517–3521
- Braun, P., Gerritse, G., van Dijl, J. M. and Quax, W. J. (1999) *Curr. Opin. Biotechnol.* **10**, 376–381
- Kunst, F., Ogasawara, N., Moszer, I., Albertini, A. M., Alloni, G., Azevedo, V., Bertero, M. G., Bessieres, P., Bolotin, A., Borchert S. et al. (1997) *Nature (London)* **390**, 249–256
- Nakamura, K., Imai, Y., Nakamura, A. and Yamane, K. (1992) *J. Bacteriol.* **174**, 2185–2192
- Honda, K., Nakamura, K., Nishiguchi, M. and Yamane, K. (1993) *J. Bacteriol.* **175**, 4885–4894
- Bunai, K., Yamada, K., Hayashi, K., Nakamura, K. and Yamane, K. (1999) *J. Biochem. (Tokyo)* **125**, 151–159
- Müller, J., Bron, S., Venema, G. and van Dijl, J. M. (2000) *Microbiology* **146**, 77–88
- Müller, J., Walter, F., van Dijl, J. M. and Behnke, D. (1992) *Mol. Gen. Genet.* **235**, 89–96
- Müller, J. (1996) *J. Bacteriol.* **178**, 6097–6104
- Hulett, F. M., Bookstein, C. and Jensen, K. (1990) *J. Bacteriol.* **172**, 735–740
- Kawamura, F. and Doi, R. H. (1984) *J. Bacteriol.* **160**, 442–434
- Carter, P., Bedouelle, H. and Winter, G. (1985) *Nucleic Acids Res.* **13**, 4431–4443
- van der Wolk, J., Klose, M., Breukink, E., Demel, R. A., de Kruijff, B., Freudl, R. and Driessen, A. J. M. (1993) *Mol. Microbiol.* **8**, 31–42
- Cabelli, R. J., Chen, L., Tai, P. C. and Oliver, D. B. (1988) *Cell* **55**, 683–692
- Schön, U. and Schumann, W. (1995) *FEMS Microbiol. Lett.* **134**, 183–188
- van Wely, K. H., Swaving, J. and Driessen, A. J. M. (1998) *Eur. J. Biochem.* **255**, 690–697
- Baneyx, F. and Georgiou, G. (1990) *J. Bacteriol.* **172**, 491–494
- van der Does, C., Manting, E. H., Kaufmann, A., Lutz, M. and Driessen, A. J. M. (1998) *Biochemistry* **37**, 201–210
- Swaving, J., van Wely, K. H. and Driessen, A. J. M. (1999) *J. Bacteriol.* **181**, 7021–7027
- Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) *Molecular Cloning: a Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor
- Vagner, V., Dervyn, E. and Ehrlich, S. D. (1998) *Microbiology* **144**, 3097–3104
- Kumamoto, C. A. and Nault, A. K. (1989) *Gene* **75**, 167–175
- van Dijl, J. M., de Jong, A., Smith, H., Bron, S. and Venema, G. (1991) *Mol. Gen. Genet.* **227**, 40–48
- Müller, J. and Harwood, C. R. (1998) *Appl. Microbiol. Biotechnol.* **49**, 321–327
- Laemmli, U. K. (1970) *Nature (London)* **227**, 680–685
- Towbin, H., Staehelin, T. and Gordon, J. (1979) *Proc. Natl. Acad. Sci. U.S.A.* **76**, 4350–4354
- Hoffschulte, H. K., Drees, B. and Müller, M. (1994) *J. Biol. Chem.* **269**, 12833–12839
- van der Does, C., den Blaauwen, T., de Wit, J. G., Manting, E. H., Groot, N. A., Fekkes, P. and Driessen, A. J. (1996) *Mol. Microbiol.* **22**, 619–629
- Weiss, J. B., Ray, P. H. and Bassford, Jr., P. J. (1988) *Proc. Natl. Acad. Sci. U.S.A.* **85**, 8978–8982
- Altman, E., Kumamoto, C. A. and Emr, S. D. (1991) *EMBO J.* **10**, 239–245

Received 4 January 2000/6 March 2000; accepted 27 March 2000